TREAT - 医索

找到约 157 条结果

Primary results from PATRICIA Cohort c (SOLTI-1303)a randomized phase ll study evaluating palbociclib withtrastuzumab and endocrine therapy in pretreated HER2.positive and PAM50 luminal advanced b

医客学院 - 会议报告集

Outcomes of Advanced MetastaticBreast Cancer(aMBC) Treated with Bria-lMT, an Allogeneic Whole-cell Immunotherapy

医客学院 - 会议报告集

DESTINY-Breast07dose-expansion analysis ofT-DXd monotherapy and T-DXd pertuzumab inpatients with previously untreated HER2 mBC

医客学院 - 会议报告集

Datopotamab deruxtecan (Dato-DXd)vs chemotherapy inpreviously-treated inoperable or metastatic hormonereceptor-positive, HER2-negative (HR HER2-) breast cancerPatient-reported outcomes(PROs) from

医客学院 - 会议报告集

Cognitive function in women with HR advanced breast cancer treated withendocrine therapy ± CDK46 inhibitors

医客学院 - 会议报告集

Association of MammaPrint index and 3-yearoutcome of patients in the FLEX Registry trial withHR HER2-early-stage breast cancer treated withchemotherapy with or without anthracycline

医客学院 - 会议报告集

Sacituzumab Tirumotecan (sac-TMT; Also Known asSKB264MK-2870)in Combination With KL-A167 (Anti-PD-L1)as First-Line Treatment for Patients With Advanced NSCLCFrom the Phase ll OptiTRoP-Lung01 Study

医客学院 - 会议报告集

Lorlatinib vs Crizotinib in Treatment-NaivePatients With Advanced ALK Non-SmallCell Lung Cancer 5-Year Progression-FreeSurvival and Safety From the CRoWN Study

医客学院 - 会议报告集

Ivonescimab combined with chemotherapy in patientswith EGFR-mutant non-squamous non-small cell lungcancer who progressed on EGFR-TKls treatment arandomized, double-blind, multi-center, phase 3 trial(HARM

医客学院 - 会议报告集

ICARUS-LUNG01 A phase 2 Study of Dato-DXd inpatients with previously treated advanced NSCLc, withsequential tissue biopsies and biomarkers analysis topredict treatment outcome

医客学院 - 会议报告集

今日实时热搜